Abstract
Objective
To evaluate the effect of canakinumab on growth parameters of patients with autoinflammatory diseases.
Methods
This retrospective study included Colchicine resistant familial Mediterranean fever (FMF), Mevalonate kinase deficiency (MKD), Tumor necrosis factor receptor-associated periodic fever syndrome (TRAPS), Deficiency of adenosine deaminase 2 (DADA2) patients treated with canakinumab for at least six consecutive months.
Results
Eleven patients with FMF, 9 with MKD, 3 with TRAPS, and 1 with DADA2 were included. The median age (range) at diagnosis and drug initiation was 6.06 (1.45–16.06) years and 9.72 (1.82–19.11) years, respectively. The mean weight, height, and BMI SD scores significantly increased after canakinumab. There were significant improvements in laboratory parameters and disease activities. However, growth parameters after the drug did not differ according to gender, the duration of diagnostic delay, and age at the diagnosis.
Conclusion
Canakinumab seems to have a positive effect on growth in patients with autoinflammatory diseases by controlling disease activity and inflammation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Oda H, Kastner DL. Genomics, Biology, and Human Illness: Advances in the monogenic autoinflammatory diseases. Rheum Dis Clin North Am. 2017;43:327–45.
Kisla Ekinci RM, Balci S, Bisgin A, Hershfield M, Atmis B, Dogruel D, et al. Renal Amyloidosis in Deficiency of Adenosine Deaminase 2: Successful Experience with Canakinumab. Pediatrics. 2018;142:e20180948.
van der Burgh R, Ter Haar NM, Boes ML, Frenkel J. Mevalonate kinase deficiency, a metabolic autoinflammatory disease. Clin Immunol. 2013;147:197–206.
ter Haar NM, Oswald M, Jeyaratnam J, Anton J, Barron KS, Brogan PA, et al. Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis. 2015;74:1636–44.
de Benedetti F, Gattorno M, Anton J, Ben-Chetrit E, Frenkel J, Hoffman HM, et al. Canakinumab for the treatment of autoinflammatory recurrent fever syndromes. N Engl J Med. 2018;378:1908–19.
Ozen S, Kone-Paut I, Gül A. Colchicine resistance and intolerance in familial mediterranean fever: Definition, causes, and alternative treatments. Semin Arthritis Rheum. 2017;47:115–20.
Balci S, Ekinci RMK, Bayazit AK, Melek E, Dogruel D, Altintas DU, et al. Juvenile systemic lupus erythematosus: A single-center experience from southern Turkey. Clin Rheumatol. 2019;38:1459–68.
Kisla Ekinci RM, Balci S, Akay E, Dogruel D, Altintas DU, Yilmaz M. Disease severity and genotype affect physical growth in children with familial mediterranean fever. Arch Rheumatol. 2019;34:i–vi. [Epub ahead of print]
Gutierrez-Suarez R, Ruperto N, Gastaldi R, Pistorio A, Felici E, Burgos-Vargas R, et al. A proposal for a pediatric version of the systemic lupus international collaborating clinics/american college of rheumatology damage index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. Arthritis Rheum. 2006;54:2989–96.
Zung A, Barash G, Zadik Z, Barash J. Familial mediterranean fever and growth: Effect of disease severity and colchicine treatment. J Pediatr Endocrinol Metab. 2006;19:155–60.
Yoldas TC, Cakar N, Basaran O, Acar B, Uncu N, Caycy FS. The effect of colchicine and disease severity on physical growth in children with familial mediterranean fever. Clin Rheumatol. 2016;35:1603–07.
Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T, et al. Criteria for the diagnosis of familial mediterranean fever. Arthritis Rheum. 1997;40:1879–85.
Ozen S, Demirkaya E, Duzova A, Erdogan O, Erken E, Gul A, et al. FMF50: A score for assessing outcome in familial mediterranean fever. Ann Rheum Dis. 2014;73:897–901.
Piram M, Koné-Paut I, Lachmann HJ, Frenkel J, Ozen S, Kuemmerle-Deschner J, et al. Validation of the autoinflammatory diseases activity index (AIDAI) for hereditary recurrent fever syndromes. Ann Rheum Dis. 2014;73:2168–73.
Neyzi O, Gunoz A, Furman A, Bundak R, Gökçay G, Darendeliler F, et al. Weight, height, head circumference and body mass index references for Turkish children. Cocuk Sagligi ve Hastaliklari Derg. 2008;51:1–14. [article in Turkish]
Kisla Ekinci RM, Balci S, Dogruel D, Altintas DU, Yilmaz M. Canakinumab in children with familial mediterranean fever: A single-center, retrospective analysis. Paediatr Drugs. 2019;21:389–95.
Balci S, Kisla Ekinci RM, Melek E, Atmyp B, Bisgin A, Yilmaz M. Phenotypic variability in two patients with tumor necrosis factor receptor associated periodic fever syndrome emphasizes a rare manifestation: Immunoglobulin a nephropathy. Eur J Med Genet. 2019;Oct 3:103780. [Epub ahead of print]
Basaran O, Uncu N, Celikel BA, Taktak A, Gur G, Cakar N. Interleukin-1 targeting treatment in familial Mediterranean fever: an experience of pediatric patients. Mod Rheumatol. 2015;25:621–4.
Funding
Funding: None
Author information
Authors and Affiliations
Contributions
Contributors: SB, MY: conceptualized and designed the study, drafted the initial manuscript, and reviewed and revised the manuscript; RMKE,DD: collected data, carried out the initial analyses, and reviewed and revised the manuscript; DUA, DD: designed the data collection instruments, and coordinated and supervised data collection, and critically reviewed the manuscript. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.
Corresponding author
Ethics declarations
Competing interest: None stated.
Rights and permissions
About this article
Cite this article
Balci, S., Ekinci, R.M.K., Dogruel, D. et al. Growth Parameters of Turkish Children With an Autoinflammatory Disease Before and After Canakinumab Treatment. Indian Pediatr 57, 637–640 (2020). https://doi.org/10.1007/s13312-020-1892-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13312-020-1892-9